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Abstract: Background: Vascular calcification is an active process that increases cardiovascular disease
(CVD) risk. There is still no consensus on an appropriate biomarker for vascular calcification. We
reasoned that the biomarker for vascular calcification is the collection of all blood components
that can be sensed and integrated into a calcification response by human vascular smooth muscle
cells (hVSMCs). Methods: We developed a new cell-based high-content assay, the BioHybrid assay,
to measure in vitro calcification. The BioHybrid assay was compared with the o-Cresolphthalein
assay and the T50 assay. Serum and plasma were derived from different cohort studies including
chronic kidney disease (CKD) stages III, IV, V and VD (on dialysis), pseudoxanthoma elasticum
(PXE) and other cardiovascular diseases including serum from participants with mild and extensive
coronary artery calcification (CAC). hVSMCs were exposed to serum and plasma samples, and
in vitro calcification was measured using AlexaFluor® -546 tagged fetuin-A as calcification sensor.
Results: The BioHybrid assay measured the kinetics of calcification in contrast to the endpoint oCresolphthalein assay. The BioHybrid assay was more sensitive to pick up differences in calcification
propensity than the T50 assay as determined by measuring control as well as pre- and post-dialysis
serum samples of CKD patients. The BioHybrid response increased with CKD severity. Further, the
BioHybrid assay discriminated between calcification propensity of individuals with a high CAC
index and individuals with a low CAC index. Patients with PXE had an increased calcification
response in the BioHybrid assay as compared to both spouse and control plasma samples. Finally,
vitamin K1 supplementation showed lower in vitro calcification, reflecting changes in delta Agatston
scores. Lower progression within the BioHybrid and on Agatston scores was accompanied by lower
dephosphorylated-uncarboxylated matrix Gla protein levels. Conclusion: The BioHybrid assay is a
novel approach to determine the vascular calcification propensity of an individual and thus may add
to personalised risk assessment for CVD.
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1. Introduction
Vascular calcification is an active process that occurs within the vessel wall and
increases the risk of cardiovascular disease (CVD) [1–3]. Moreover, coronary artery calcification (CAC) is considered a marker for cardiovascular burden. High abundance of
calcification present at any vascular site relates to approximately a 3.5-fold increase for CVD
events [4]. Additionally, CAC progression is associated with a 17-fold increased risk of
myocardial infarction [5]. Therefore, the means to measure vascular calcification amount or
progression rate have the potential to accurately predict the risk for cardiovascular events.
The current methods to detect and assess calcification in vivo aim to visualise precipitated calcium phosphate deposition in the vasculature. Circulating biomarkers that reflect
the propensity to develop and aggravate vascular calcification have not been identified so
far. In vitro, diagnostics by the T50 assay may infer calcification propensity in serum [6].
Given this, the T50 assay is based on a chemical reaction and is largely affected in samples
wherein a mineral imbalance or decreased circulating fetuin-A or albumin is present, thus
lacking biological cause or consequence. In this paper, we reason that the circulating
biomarker for vascular calcification is not a single component but the collection of all
components in circulation.
As readout of this composite biomarker, we selected in vitro calcification mediated
by human vascular smooth muscle cells (hVSMCs), considered by many as the protagonists in vascular calcification [3]. This paper describes the BioHybrid assay, a cell-based
assay for measuring the composite biomarker of vascular calcification. We measured the
BioHybrid response that we consider to be the in vitro development of calcification. This
was performed using either serum or plasma samples from several cohort studies. Cohorts
included were that of variant stages of CKD wherein vascular calcification is synonymous
with disease progression as well as PXE, a genetic disorder wherein ectopic mineralisation
of soft tissue is present. In addition, we studied two cohort studies wherein enrolment
was based on CVD status: one high vs. low CAC (determined by Agatston scoring), and
the other was aortic valve calcification (AVC) with CAC. From both CVD cohorts, further
information on Agatston scoring data was available.
In the following, we demonstrate that there is a strong and significant correlation between the Agatston score and the BioHybrid calcification readout. Additionally, serum and
plasma samples from the various cohorts responded with increased in vitro calcification
in the BioHybrid assay compared to respective controls. Serum or plasma samples from
participants with extensive calcification responded with a faster development of in vitro
hVSMC calcification than those with milder calcification. The BioHybrid calcification assay
presented in this paper is an informative strategy to determine an individual’s vascular
calcification propensity.
2. Materials and Methods
2.1. hVSMC Culturing and Characterisation
hVSMCs were isolated from non-atherosclerotic abdominal aortas of surgical biopsies
in accordance with MUMC+ research and diagnostic procedure. Collection, storage and
use of tissue and patient data were performed in agreement with the Dutch Code for Proper
Secondary Use of Human Tissue (https://www.federa.org/codes-conduct accessed on 30
July 2021). This study complies with the Declaration of Helsinki.
Briefly, human vascular tissue samples were washed in phosphate buffered saline
(PBS) before intima, fat and connective tissue was removed. Tissue was then cut into
small fragments (approx. 2–5 mm in diameter) and left in M199 medium (Gibco, Bleiswijk,
the Netherlands) containing 20% fetal bovine serum (FBS), 1% penicillin/streptomycin
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(PS, Gibco, Bleiswijk, the Netherlands) and 1% Amphotericin B on laminin coated plates
(#L2020, Sigma, Saint Louis, MO, USA). When outgrowing cells reached confluency, they
were passaged 1:2 on laminin-coated plates for two further passages. hVSMCs were
routinely cultured in M199 medium with 20% FBS and 1% PS. For experiments, cells were
used between passages 5–10. All samples were mycoplasma tested.
For characterisation (Supplemental Figure S2), hVSMCs were fixed in 4% paraformaldehyde before blocking in 2% BSA, 0.1% triton in PBS for one hour. Primary antibodies were
incubated overnight at 4 ◦ C: alpha-Smooth Muscle Actin (αSMA) 1:200 (DAKO, Glostrup,
Glostrup, Denmark, M0851), phosphorylated-Myosin Light Chain (pMLC) 1:200 (Cell
Signaling, Danvers, MA, USA, 3675S), Calponin (CNN1) 1:200 (Abcam, Cambridge, UK,
ab46794), Smooth Muscle protein 22-alpha (SM22a) 1:200 (Abcam, Cambridge, UK ab14106)
and S100 calcium-binding protein A4 (S100A4) 1:200 (DAKO, Glostrup, Glostrup, Denmark,
A5114). Cells were incubated with secondary antibodies for one hour at room temperature:
anti-mouse FITC 1:250 (Hycult Biotech, Uden, The Netherlands, HP2001) or anti-rabbit
FITC 1:250 (DAKO, Glostrup, Glostrup, Denmark, F0205). Before imaging, cells were incubated with 40 ,6-diamidino-2-phenylindole (DAPI) for one minute. Imaging was performed
on the Cytation 3 system on 20× magnification (BioSPX, Abcoude, The Netherlands).
2.2. BioHybrid Assay
For calcification experiments, hVSMCs were seeded in culture well plates at a density
of 10–15 × 103 cells/cm2 . After 24 h, hVSMCs were cultured in calcification medium
(M199, 5% human serum or plasma, 1% PS and 3.6 mM Ca2+ ) for up to 14 days. Plasma
samples were further supplemented with 143 µM Hirudin to prevent coagulation upon
re-calcifying plasma. As positive control, a 0.5% serum/plasma condition was used due to
the higher magnitude of calcification. For the BioHybrid assay, fetuin-A-AlexaFluor® -546
(1–3 µg/mL; prepared in-house) and Hoechst 33,342 (1 µg/mL, Invitrogen, Waltham, MA,
USA) were supplemented at the start of the experiment. At various time points after
calcification induction, red fluorescent protein (RFP) and DAPI channel (cell count) were
imaged up to 14 days. After calcification was detected, cells were imaged regularly to
follow calcification progression. Imaging was done with the Cytation 3 system (BioSPX,
Abcoude, the Netherlands) and analysed using Gen5 software v.2.9 (BioTek, Abcoude, the
Netherlands). As readout RFP confluence per well was normalised against cell count.
2.3. o-Cresolphthalein Assay
The o-Cresolphthalein assay (Randox, London, UK) was carried out according to manufacturer’s instructions. In brief, cells were washed twice in PBS and mineral deposits were
solubilised in 0.1 M HCl for 2 h. After mineral deposits were solubilised, o-Cresolphthalein
was added, which forms a violet complex with the calcium in the supernatant. A calcium
standard was prepared with a range 0–2.54 mmol/L and concentration was determined by
measuring absorbance at 570 nm.
2.4. T50 Assay
The T50 assay was performed as previously described [6]. In brief, sera of patients were
centrifuged at 10,000 g and the supernatant was mixed with high concentrations of calcium
and phosphate solutions to induce calciprotein particle (CPP) formation. Pipetting was
performed with a high precision pipetting device (Liquidator, Mettler Toledo, Greifensee,
Switzerland) and formation of CPP was monitored in a time-resolving manner using a
standard nephelometer (Nephelostar, BMG Labtech, Ortenberg, Germany). The results
were used to calculate the one-half maximal transition time, hence T50.
2.5. Serum and Plasma Preparation
Serum and EDTA plasma samples were obtained from several cohort studies. Enrolment to the cohorts was based on clinical diagnosis of the following parameters: CKD5D,
CKD 3 to 5, PXE, high and low CAC score and AVC. In the AVC trial, patients received
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either vitamin K1 supplementation or placebo [7]. Serum and plasma of healthy individuals
were used as a negative control. All patients and healthy volunteers had given written
consent. This research and sample collection were approved by the Ethics Committee of
the RWTH Aachen University Hospital, Aachen and Sidney Kimmel Medical College at
Thomas Jefferson University, Philadelphia, Pennsylvania and conducted in accordance
with the Declaration of Helsinki.
2.6. Dephosphorylated-Uncarboxylated Matrix Gla Protein (dp-ucMGP) Measurement
Plasma dp-ucMGP levels were determined using the commercially available IVD
CE-marked chemiluminescent InaKtif MGP assay on the IDS-iSYS system (IDS, Boldon,
UK). In brief, samples and internal calibrators were incubated with magnetic particles
coated with murine monoclonal antibodies against dp-MGP, acridinium-labelled murine
monoclonal antibodies against ucMGP and an assay buffer. The magnetic particles were
captured and washed to remove unbound analyte. Trigger reagents were added; the
resulting light emitted by the acridinium label is directly proportional to the level of dpucMGP in the sample. The within-run and total variations of this assay were 0.8–6.2% and
3.0–8.2%, respectively. The assay measuring range was between 300 and 12,000 pmol/L
and was linear up to 11,651 pmol/L [8]. All assays were performed by Coagulation Profile
laboratories, Maastricht, the Netherlands.
2.7. Data Analysis and Statistics
Real-time calcification development over time was analysed using Gen5 version 2.9
(BioTek, Abcoude, the Netherlands). Confluence of Alexa 546 signal was determined and
normalised against cell count. Data are presented as mean ± standard deviation (SD). For
over-time measurements, data is presented as mean. Non-parametric Mann−Whitney
U test was performed for comparison between two groups. For more than two groups,
significance was determined using one-way analysis of variance (ANOVA; Kruskal−Wallis)
with comparison between groups by Dunn’s multiple comparison test. For correlation
determination, a linear regression model and R2 was determined. Statistical significance
was defined as p ≤ 0.05 (*), p ≤ 0.01 (**), p ≤ 0.001 (***) and p ≤ 0.0001 (****).
3. Results
3.1. Development of the BioHybrid Calcification Assay
Thus far, measurement of in vitro hVSMC calcification is only possible via end-point
assays using either Alizarin Red or o-Cresolphthalein quantification. We developed a novel
in vitro hVSMC calcification assay in which calcification development can be followed in
real-time using fluorescently labelled fetuin-A-AlexaFluor® -546. To test the robustness of
our live calcification assay, we compared the BioHybrid assay with the o-Cresolphthalein
method, which measures calcification as calcium/protein ratio. We found a strong correlation (R2 = 0.72) between fetuin-A-AlexaFluor® -546 fluorescence per cell (% RFP/cell count)
and o-Cresolphthalein (µg Ca2+ /µg protein; Figure 1A; representative images Figure
1C; curve fit Figure S1C,D). Moreover, the BioHybrid assay has a dynamic range and is
significantly more sensitive in both the earlier and lower detection of in vitro calcification
compared to the o-Cresolphthalein method (Figure 1B).
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dynamic range and is significantly more sensitive in both the earlier and lower detection
of in vitro calcification compared to the o-Cresolphthalein method (Figure 1B).

Figure 1. BioHybrid calcification assay. (A) Live calcification assay compared to the o-Cresolphthalein
Figure 1. BioHybrid calcification assay. 2(A) Live calcification assay compared to the omethod provides a good correlation, R = 0.72. (B) Relative increase in calcification of both BioHybrid
Cresolphthalein method provides a good correlation, R2 = 0.72. (B) Relative increase in calcification
and o-Cresolphthalein methods. (C) Representative images (4× magnification) of the BioHybrid
of both BioHybrid and o-Cresolphthalein methods. (C) Representative images (4× magnification)
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the BioHybrid.
Elasticum Patients and Patients with Coronary Artery Calcification as Compared to Control
3.3. Calcification Propensity
in Cohorts
of Chronic
Kidney
Disease Patients,
Pseudoxanthoma
Next, we
compared
hVSMC
calcification
induction
by serum of a cohort
Elasticum Patients
and Patients
Calcification
to Control
participants
withwith
CKDCoronary
stages 3,Artery
4 or 5 against
a poolasofCompared
healthy donors.
As shown in Fig
Next, we3A,
compared
calcification
induction
of a cohort
of participants
healthyhVSMC
controls
had the lowest
rate by
of serum
calcification
development
per hour. Ser
with CKD stages
3, 4the
or 5CKD5
against
a poolparticipants
of healthy donors.
shown
in Figure
3A,hVSMC
healthycalcificat
from
cohort
showedAsthe
highest
rate of
controls had the lowest rate of calcification development per hour. Serum from the CKD5
cohort participants showed the highest rate of hVSMC calcification followed by CKD4
and CKD3, respectively (trend; p = 0.0708). We observed a positive association of in vitro
calcification rate from serum with increasing CKD severity (Figure 3B; p = 0.0859).
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Figure 3. hVSMC calcification propensity of serum or plasma from cohorts of CKD stages 3–5, PXE
Figure
3. hVSMC
calcification
propensity
of serum or plasma
cohorts of CKD
stages 3–5,
and high
vs. low
Agatston score.
(A) Calcification
rate in from
the BioHybrid
calcification
assay. A
PXE and high vs. low Agatston score. (A) Calcification rate in the BioHybrid calcification assay. A
trend was found in serum from CKD patients (n = 4) compared to control. (B) Calcification signal
trend was found in serum from CKD patients (n = 4) compared to control. (B) Calcification signal
after 7 days in BioHybrid assay showing an increase in calcification when challenged with CKD
after 7 days in BioHybrid assay showing an increase in calcification when challenged with CKD
serum(n(n= =4).4).(C)
(C)Calcification
CalcificationofofPXE
PXEplasma
plasma(n(n= =3)3)compared
comparedtototheir
theirspouses
spouses(n(n= =3)3)and
andhealthy
healthy
serum
controls.
A
significant
increase
in
in
vitro
calcification
was
found
in
PXE
plasma
compared
their
controls. A significant increase in in vitro calcification was found in PXE plasma compared tototheir
spouses(p(p= =
0.0012).
(D)
hVSMC
calcification
serum
from
low
6) vs.
high
6) Agatston
spouses
0.0012).
(D)
hVSMC
calcification
of of
serum
from
low
(n =(n6)=vs.
high
(n =(n6)=Agatston
scoregroups.
groups.AAsignificant
significantincrease
increaseinincalcification
calcificationwas
wasfound
foundfrom
fromserum
serumof
ofhigh
highAgatston
Agatston scoring
score
scoring
compared
to the
low Agatston
score group
(p = 0.0022).
(E) Correlation
of Agatston
group group
compared
to the low
Agatston
score group
(p = 0.0022).
(E) Correlation
of Agatston
score vs.
score
vs. calcification.
in vitro calcification.
A significant
correlation
was
in Agatston
the high Agatston
score
in vitro
A significant
correlation
was found
in found
the high
score group
(R2 = 0.68;
p = in
0.0436)
butAgatston
not in thegroup.
low Agatston
group. ** p < 0.01.
group
(R2 = 0.68;
p = 0.0436)
but not
the low
** p < 0.01.

We
compared hVSMC
hVSMCcalcification
calcification
induced
plasma
samples
PXE
We also
also compared
induced
by by
plasma
samples
fromfrom
a PXEacohort
cohort
against
plasma
spouse
controls
and plasma
healthy
controls.
found
against
plasma
from from
spouse
controls
and plasma
fromfrom
healthy
controls.
We We
found
that
that
plasma
the PXE
cohort
induced
in vitro
calcification
compared
both
plasma
fromfrom
the PXE
cohort
induced
in vitro
calcification
faster faster
compared
to bothtocontrol
control
and spouse
This difference
was significant
between
the PXE
and spouse
plasmaplasma
(Figure (Figure
3C). This3C).
difference
was significant
between the
PXE group
and
group
and
spouse
controls
(Figure
3C;
p
=
0.0012).
spouse controls (Figure 3C; p = 0.0012).
Next,
Next,we
weassessed
assessedhow
howthe
theBioHybrid
BioHybridsystem
systemresponded
respondedtotoserum
serumfrom
fromindividuals
individuals
knowntotohave
have
either
mild
extensive
CAC
as determined
by Agatston
scores.
For
known
either
mild
or or
extensive
CAC
as determined
by Agatston
scores.
For this,
this,
we tested
from individuals
with aeither
high (>1500)
lowAgatston
(<50) Agatston
we
tested
serumserum
from individuals
with either
high a(>1500)
or low or
(<50)
score.
vitro calcification
was significantly
higher
fromof
serum
of the
high Agatston
score
Inscore.
vitro In
calcification
was significantly
higher from
serum
the high
Agatston
score group
group compared
to the
low Agatston
score (Figure
group (Figure
p = 0.0022).
High Agatston
compared
to the low
Agatston
score group
3D; p =3D;
0.0022).
High Agatston
score
score patient
displayed
a significant
linear regression
withcalcification
in vitro calcification
patient
samplessamples
displayed
a significant
linear regression
with in vitro
(Figure
2
2
(Figure
3E; Rwhereas
= 0.68) whereas
no such correlation
was observed
in the
low Agatston
group
3E;
R = 0.68)
no such correlation
was observed
in the low
Agatston
group (data
(data
not shown).
not
shown).
3.4.Calcification
CalcificationPropensity
PropensityofofSerum
Serumfrom
fromAortic
AorticValve
ValveCalcification
CalcificationPatients
Patientswith
withVitamin
VitaminK1
3.4.
K1 Treatment
Treatment
Lastly, we tested serum samples from a cohort of individuals with AVC and CAC who
Lastly, we tested serum samples from a cohort of individuals with AVC and CAC
participated in a proof-of-concept study with either vitamin K1 (phylloquinone) or placebo
who participated in a proof-of-concept study with either vitamin K1 (phylloquinone) or
treatment for one year [7]. When comparing serum from the start of the trial with serum
placebo treatment for one year [7]. When comparing serum from the start of the trial with
after 12 months of vitamin K1 supplementation, we found a reduction of in vitro hVSMC
serum
after 12(vitamin
months K1
of vitamin
supplementation,
we serum
found from
a reduction
of in group
vitro
calcification
−21.4%;K1
Figure
4A). Conversely,
the placebo
hVSMC
calcification
(vitamin
K1
−21.4%;
Figure
4A).
Conversely,
serum
from
the
placebo
did not have the same response, whereas in fact an increase in in vitro hVSMC calcification
group
did not
have +73.2%;
the sameFigure
response,
whereas
fact an
in in vitro hVSMC
was found
(placebo
4A). There
wasin
a trend
in increase
hVSMC calcification
between
calcification
found
+73.2%;
Figure 4A). (Figure
There was
12 months ofwas
vitamin
K1(placebo
and placebo
supplementation
4A; pa= trend
0.06). in hVSMC
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calcification between 12 months of vitamin K1 and placebo supplementation (Figure8 of
4A;
p = 0.06).

Figure 4. hVSMC calcification induction from serum of AVC and CAC patients. (A) In vitro calcificaFigure 4. hVSMC calcification induction from serum of AVC and CAC patients. (A) In vitro
tion after 1 year vitamin K1 supplementation (n = 22) or placebo (n = 20). Supplementation of vitamin
calcification after 1 year vitamin K1 supplementation (n = 22) or placebo (n = 20). Supplementation
K1 showed a decreased response to in vitro calcification development comparing baseline serum to
of vitamin K1 showed a decreased response to in vitro calcification development comparing
12
months.
Conversely,
the placebo
groupthe
exhibited
in vitro increased
calcification
in
baseline
serum
to 12 months.
Conversely,
placeboincreased
group exhibited
in development
vitro
our
assay
(p
=
0.06).
(B)
Dp-ucMGP
change
after
1
year.
Dp-ucMGP
levels
significantly
decreased
calcification development in our assay (p = 0.06). (B) Dp-ucMGP change after 1 year. Dp-ucMGP
following
1 year ofdecreased
vitamin K1
supplementation
(n = 18)K1
compared
to the placebo
(ncompared
= 20) group
levels
significantly
following
1 year of vitamin
supplementation
(n = 18)
(p the
< 0.0001).
Agatston
No differences
were found
either
CAC orwere
AVC
to
placebo(C)
(n Development
= 20) group (p of
< 0.0001).
(C)score.
Development
of Agatston
score.in
No
differences
found
in both
either
CAC
or AVC
score in
the vitamin
K1 (CAC
n =(CAC
18; AVK
= 19)
and
score in
the
vitamin
K1 (CAC
n =both
18; AVK
n = 19) and
placebo
n = n13;
AVK
n =placebo
16) group.
(CAC
n 0.0001.
= 13; AVK n = 16) group. **** p < 0.0001.
**** p <

Next,
is is
both
a
Next,we
weassessed
assesseddp-ucMGP
dp-ucMGPlevels
levelsbetween
betweenthe
thetwo
twogroups,
groups,asasdp-ucMGP
dp-ucMGP
both
vitamin
K-dependent
protein
andand
a circulating
marker
associated
withwith
the development
a vitamin
K-dependent
protein
a circulating
marker
associated
the development
of vascular
calcification
(Figure
4B).Dp-ucMGP
Dp-ucMGP plasma levels
significantly
deof
vascular
calcification
(Figure
4B).
levelswere
were
significantly
creased in in
thethe
serum
of individuals
who who
received
vitamin
K1 supplementation
(p < 0.0001).
decreased
serum
of individuals
received
vitamin
K1 supplementation
(p <
Comparing
the delta
Agatston
scores scores
(change
in calcification
between
pre- vs.
0.0001).
Comparing
theindelta
in Agatston
(change
in calcification
between
pre-postvs.
supplementation), no differences
between
vitamin
K1K1ororplacebo
observed
post-supplementation),
no differences
between
vitamin
placebocould
could be
be observed
(Figure 4C).
4C).
(Figure
4. Discussion
Discussion
4.
Vascular calcification
calcification independently
independently predicts
predictsthe
the risk
risk of
of cardiovascular
cardiovasculardisease
disease[4].
[4].
Vascular
Vascular
calcification
can
be
measured
clinically
by
imaging
techniques
such
as
computed
Vascular calcification can be measured clinically by imaging techniques such as computed
tomography, intravascular
and magnetic
resonance
imaging. imaging.
These techniques
tomography,
intravascularultrasound
ultrasound
and magnetic
resonance
These
are
expensive
and
place
burdens
on
patients.
Measurement
of
circulating
techniques are expensive and place burdens on patients. Measurement of biomarkers
circulating
can be a more
and less burdensome
alternativealternative
for diagnosis
of vascular
biomarkers
can cost-effective
be a more cost-effective
and less burdensome
for diagnosis
of
calcification. However, to date, no such biomarkers have been identified that adequately
vascular calcification. However, to date, no such biomarkers have been identified that
reflect the calcification burden.
adequately reflect the calcification burden.
This paper describes the BioHybrid assay for determining the vascular calcification
This paper describes the BioHybrid assay for determining the vascular calcification
propensity of an individual by measuring the calcification response of cultured hVSMCs
propensity of an individual by measuring the calcification response of cultured hVSMCs
brought into contact with serum or plasma of that individual. The BioHybrid assay is built
brought into contact with serum or plasma of that individual. The BioHybrid assay is built
on the idea that the circulating biomarker of vascular calcification is not a single biomarker
on the idea that the circulating biomarker of vascular calcification is not a single biomarker
but a collection of circulating components. These can be sensed, integrated, and converted
but a collection of circulating components. These can be sensed, integrated, and converted
into a measurable calcification response by cultured hVSMCs. We describe the setup of the
into a measurable calcification response by cultured hVSMCs. We describe the setup of
BioHybrid assay and its first validation.
the BioHybrid assay and its first validation.
Two methods are widely used for measurement of precipitated calcium salts in cell
Two
are are
widely
usedRed
for staining
measurement
of precipitated calcium
salts in and
cell
culture
inmethods
vitro. These
Alizarin
and o-Cresolphthalein
quantification,
culture
in
vitro.
These
are
Alizarin
Red
staining
and
o-Cresolphthalein
quantification,
and
both are endpoint measurements. In order to be able to retrieve kinetics of calcification in
both
are endpoint
measurements.
In order
to beemploys
able to retrieve
kinetics
of calcification
the presence
of hVSMCs,
the BioHybrid
assay
fluorescently
labelled
fetuin-A in
in
the
presence
of
hVSMCs,
the
BioHybrid
assay
employs
fluorescently
labelled
fetuin-A
in
combination with live cell imaging. Fetuin-A is a protein abundantly present in the blood
combination
withtolive
celltoimaging.
is aaffinity
protein[10].
abundantly
present
the blood
with the ability
bind
mineralsFetuin-A
with high
The amount
of in
calcification
with
the
ability
to
bind
to
minerals
with
high
affinity
[10].
The
amount
of
calcification
®
measured with fetuin-A-AlexaFluor -546 significantly correlated with the results obtained
®
measured
with fetuin-A-AlexaFluor
significantly
correlated
with
the hVSMC
results
with the o-Cresolphthalein
method (R2 -546
= 0.72).
During the early
phase of
in vitro
2 = 0.72). During the early phase of in vitro
®
obtained
with
the
o-Cresolphthalein
method
(R
calcification, the fetuin-A-AlexaFluor -546 probe is vastly superior with a greater degree
®-546 probe is vastly superior with a greater
hVSMC
calcification,
the fetuin-A-AlexaFluor
of sensitivity
than o-Cresolphthalein.
Additionally,
end-point assays require multiple
replicates to record calcification development over time, which also increases chances of
variability. With the BioHybrid assay, we exploit live-cell imaging, enabling us to follow
the calcification development of a single condition and its replicates over time. Trialling the
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BioHybrid assay with a variety of both human serum and plasma samples grants further
efficacy to the use of the BioHybrid assay as well as confidence in its robustness.
To date, most measurements are based on single protein biomarkers. The T50 assay
was the first attempt to more comprehensively analyse the calcification propensity test
by measuring the transformation of CPPs [6,11]. The T50 determines poor cardiovascular
prognosis and has been shown to be associated with CVD, all-cause mortality and aortic
stiffening in renal disease [12–14] based on serum factors and time to form CPPs. However,
this assay is solely based on a chemical reaction without considering the vascular influence.
After optimizing calcification conditions, we tested whether T50 results could be replicated in the BioHybrid, comparing serum samples from pre- and post-dialysis. We found
that the BioHybrid assay could measure differences between pre- and post-dialysis serum.
Additionally, the BioHybrid could also discriminate between post-dialysis and control
serum, i.e., a discrimination that the T50 assay was unable to make. The comparison between pre- and post-dialysis was performed since dialysis removes circulating components
involved in calcification. The T50 is based on systemic proteins (pro/anticalcification) and
minerals (i.e., phosphate, calcium and magnesium). However, factors impacting vascular
cells that are involved in the calcification process (i.e, hVSMCs) are not measured in the
T50. In contrast to the T50, these factors (i.e., toxins, cytokines) are also measured with
the BioHybrid assay. Thus, the BioHybrid is measuring the sum of all factors, including
vascular response, contributing to vascular calcification. Following the samples in real-time,
six days in culture revealed a greater difference between pre- and post-dialysis as well
as between post-dialysis and control. In addition to this, the ability to follow the same
sample live and its replicates in real-time allows us to find specific responses as to the rate
of calcification development. The differential response is possibly representative of the
varying profiles exhibited by individuals on dialysis and requires further investigation.
We suggest that as a next step, a more clinically coupled application of the BioHybrid in
dialysis could serve as a warning or signal to non-response to treatments.
Given our application of the BioHybrid assay to the serum of CKD5D patients, we
next checked how serum or plasma samples from a variety of cohorts would respond. This
was done with serum or plasma samples from cohort participants with CKD stages 3–5,
PXE and high vs. low Agatston scores.
PXE is a monogenetic liver disorder, and reduced plasma anti-mineralisation capacity
is observed along with extensive ectopic calcification. As PXE is a metabolic disorder,
assessing whether the blood-metabolites produced by the liver cause ectopic mineralisation
makes it ideal for our BioHybrid screening [15,16]. We found that PXE plasma samples had
a significantly increased effect on in vitro hVSMC calcification when compared to plasma
from spouse controls. This suggests a circulating factor causing increased in vitro ectopic
calcification. Further research is required to define the factors that are involved in PXE
mediated vascular calcification, but our research indicates that the BioHybrid platform can
distinguish factors present in the blood that affect calcification. Further, the BioHybrid
could serve as a screening platform of drugs that target PXE induced mineralisation.
Severe renal artery and aortic calcification, CAC and AVC, are often symptomatic
in CKD [17]. Additionally, up to 93% of CKD individuals on dialysis display imageable
vascular calcification [18,19]. The Agatston score is evaluated as the gold-standard clinical
predictor for the accumulation and progression of vascular calcification over time [5,20].
Further, CAC score is used to identify non-CKD high-risk individuals that need immediate
medical attention or intervention [21]. In the BioHybrid assay, we found that all cohort
patients (CKD stages 3–5, PXE and high Agatston scoring) showed increased in vitro
calcification compared to respective controls. In vitro calcification progression with CKD5
serum was faster and greater than that of serum from CKD 3 and 4 patients and non-CKD
controls. Serum samples from CKD 4 had the second greatest induction, followed by
CKD3 serum and lastly control serum. This is somewhat representative of the clinical
situation wherein an increase of severity of CKD is associated with an increase in vascular
calcification [22–24].
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Next, we tested whether serum from high and low Agatston scored individuals
would have an influence in the BioHybrid assay. We found that hVSMCs calcification
with serum from the high Agatston score group developed more calcification compared to
the low Agatston score group. We further observed a positive correlation of calcification
development within the high Agatston score group which was non-existing in patients
with low Agatston score. Lastly, we tested serum samples from a cohort of participants
with CVD diagnosis who had received either vitamin K1 supplementation or placebo for
12 months. Interestingly, serum from the vitamin K1 supplementation group had a reduced
effect on in vitro hVSMC calcification compared to serum from the placebo group following
12 months of supplementation. The effect was most likely caused by changes in serum
composition induced by vitamin K1, which is known to act as cofactor to activate vitamin
K-dependent proteins (VKDPs) involved in the inhibition of calcification. This was not a
direct effect of vitamin K serum levels as exogenous addition of vitamin K1 to serum had
no effect on hVSMC calcification. We postulate that the protective effect of vitamin K1 in
our BioHybrid assay is based on post-translational modifications of VKDP.
Although in the vitamin K1 study, all groups’ cardiovascular status continued to
decline, the placebo group had on average a 25% increase in Agatston scoring during the
12-month period, whereas the vitamin K1 group had only a 12% increase [7]. Combined,
these results indicate that the BioHybrid assay might have the potential to predict in vivo
vascular calcification development and has potential sensitivity to distinguish amongst
highly susceptible at-risk individuals.
Serum levels of the vitamin K-dependent protein and circulatory biomarker dpucMGP positively associates with vascular calcification [4,25]. Vitamin K supplementation
decreased dp-ucMGP levels in all samples, yet this was not reflected in the clinical outcome
for development of vascular calcification. We reason that dp-ucMGP is only reflective as
a single biomarker involved in vascular calcification, a multifactorial biological process.
Whereas dp-ucMGP reflects the status of a singular protein in circulation, the BioHybrid
assay employs the whole blood compartment. We hypothesise that the BioHybrid platform
can become an assay for clinical risk assessment of vascular calcification progression.
5. Conclusions
In conclusion, we present a novel BioHybrid assay that can determine personal vascular calcification propensity. Using fetuin-A-AlexaFluor® -546, we developed a real-time
in vitro calcification assay that can give a quantifiable readout of in vitro hVSMC calcification development over time. We showed that vascular calcification is the consequence of
the collection of all blood components that can be sensed and integrated into a calcification
response by human vascular smooth muscle cells (hVSMCs). Further, the sensitivity of
this assay has been demonstrated in response to dialysis, vitamin K treatment, as well
as both metabolic and non-metabolic disorders that directly affect cardiovascular status.
We propose wide scale application of this assay in larger cohorts to further validate the
potential application of the BioHybrid assay as a non-invasive cardiovascular diagnostic
tool, which may ultimately add to personalised risk assessment for CVD (Figure 5).
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